chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Fierce cold; shivers; fever; headache; migraine; vomiting; Insomnia; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had slight berry allergy which was not dangerous. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Mar2021 at 13:30 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 at 23:00, the patient experienced fierce cold, shivers, fever, headache, migraine, vomiting and insomnia. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the adverse events. The clinical outcome of the events fierce cold, shivers, fever, headache, migraine, vomiting and insomnia were resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Disturbance in attention, Fatigue, Heart rate
Clinical narrative: Hips, vertebrae (from head to hips) ached; Heart would race randomly; Exhausted; pulse was up to 129.; around 6 hours after shot, Joints started to ache; Chills; Trouble focusing and completing simple tasks; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 18Apr2021 at 09:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included juvenile rheumatoid arthritis (currently in remission) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included over the counter multivitamin (MANUFACTURER UNKNOWN) on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 28Mar2021 at 09:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Patient had no known allergies to food, medication or other products. On 18Apr2021, about 6 hours after shot, the patient joints started to ache. She had trouble focusing and completing simple tasks. She experienced chills off and on but didn't actually have a fever. The next morning, on 19Apr2021, patient was exhausted and her hips, vertebrae (from head to hips) ached. Her heart would race randomly and just sitting up in bed to drink water made her heart rate alarm go off and notify her that her pulse was up to 129. The patient spent the day in bed but had her pulse alarm go off several times an hour. The patient started to felt better/more like herself after taking 800mg of MOTRIN about 34 hours after her shot. It was now two days (50 hours exactly) from when she received her second shot and she felt perfectly fine. Her heart was not racing randomly, either. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with 800mg of ibuprofen (MOTRIN). On 18Apr2021, the patient pulse rate was measured and the result was 129 (unknown unit). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events trouble focusing, heart racing, joint started to ache, exhaustion, pulse was up to 129, hips, vertebrae (from head to hips) ached and chills were resolved on 20Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, Palpitations, Spinal pain
Clinical narrative: Hips, vertebrae (from head to hips) ached; Heart would race randomly; Exhausted; pulse was up to 129.; around 6 hours after shot, Joints started to ache; Chills; Trouble focusing and completing simple tasks; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 18Apr2021 at 09:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included juvenile rheumatoid arthritis (currently in remission) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included over the counter multivitamin (MANUFACTURER UNKNOWN) on an unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 28Mar2021 at 09:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Patient had no known allergies to food, medication or other products. On 18Apr2021, about 6 hours after shot, the patient joints started to ache. She had trouble focusing and completing simple tasks. She experienced chills off and on but didn't actually have a fever. The next morning, on 19Apr2021, patient was exhausted and her hips, vertebrae (from head to hips) ached. Her heart would race randomly and just sitting up in bed to drink water made her heart rate alarm go off and notify her that her pulse was up to 129. The patient spent the day in bed but had her pulse alarm go off several times an hour. The patient started to felt better/more like herself after taking 800mg of MOTRIN about 34 hours after her shot. It was now two days (50 hours exactly) from when she received her second shot and she felt perfectly fine. Her heart was not racing randomly, either. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with 800mg of ibuprofen (MOTRIN). On 18Apr2021, the patient pulse rate was measured and the result was 129 (unknown unit). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events trouble focusing, heart racing, joint started to ache, exhaustion, pulse was up to 129, hips, vertebrae (from head to hips) ached and chills were resolved on 20Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Myalgia, Nausea
Clinical narrative: Tiredness; headache; joint and muscle pain; joint and muscle pain; fever; nausea; vomiting; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 18Apr2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), cyanocobalamin (B 12), colecalciferol (VIT D3), zinc (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EL3302) via an unspecified route of administration in the left arm on 21Mar2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 22:00, the patient experienced tiredness, headache, joint and musical pain, fever, nausea, and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, headache, joint and musical pain, fever, nausea, and vomiting was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Tiredness; headache; joint and muscle pain; joint and muscle pain; fever; nausea; vomiting; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 18Apr2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), cyanocobalamin (B 12), colecalciferol (VIT D3), zinc (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EL3302) via an unspecified route of administration in the left arm on 21Mar2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 22:00, the patient experienced tiredness, headache, joint and musical pain, fever, nausea, and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, headache, joint and musical pain, fever, nausea, and vomiting was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Pain, Pyrexia
Clinical narrative: 12 days after second shot, Fever 100F, 13 days after second shot, Fever 99.9; Body aches; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0150) via an unspecified route of administration in the arm left on 06Apr2021 at 12:30 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6207) via an unspecified route of administration in the arm left on 16Mar2021 at 12:30 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 14:30, 10 days after second shot, the patient experienced moderate fatigue. On17Apr2021, 11 days after second shot, the patient had moderate fatigue. On18Apr2021, 12 days after second shot, the patient experienced  fever of 100 F, fatigue moderate and body aches. On 19Apr2021,13 days after second shot, the patient had fever of 99.9 and fatigue moderate. It was reported that all the symptoms were resolved with Tylenol and rest. On 18Apr2021, the patient underwent lab tests and procedures which included body temperature test and the result was 100 F and on 19Apr2021, the result was 99.9 (unspecified unit).Therapeutic measures included treatment with Tylenol. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, fever 100F, 99.9 and body aches was resolved on an unknown date of Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Strong pain located in the place of the shot; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Apr2021 at 11:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food, or other products. It was unknown if the patient was pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications. On 19Apr2021 at 18:30, the patient experienced strong pain located in the place of the shot. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event and included treatment with pain killer (unspecified) in the afternoon (PM) and acetaminophen (EQUATE) 500mg. The clinical outcome of the event strong pain located in the place of the shot was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: U
Vaccine: COVID19
Symptoms: Neck pain
Clinical narrative: Left side of neck in pain; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old patient of unknown gender received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 19Apr2021 at 13:15 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified blood pressure medications from an unknown date and unknown if ongoing. On 19Apr2021 at 13:15, left side of the patient's neck was in pain. The patient had it, since the first vaccination. The pain was worse at the time of report and the patient had no health insurance to go to the hospital. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event left side of neck in pain was not resolved at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Malaise, Nausea
Clinical narrative: injection site pain; tiredness; headache; fever; nausea; feeling unwell; dizziness; productive cough (yellow-brown); sneezing; weezing (no deep breaths); This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 11:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 the patient experienced injection site pain, tiredness, headache, fever, nausea, feeling unwell, dizziness, productive cough (yellow-brown), sneezing and wheezing (no deep breaths). Therapeutic measures were not taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event injection site pain, tiredness, headache, fever, nausea, feeling unwell, dizziness, productive cough (yellow-brown), sneezing and wheezing (no deep breaths) were recovered with sequelae on Apr2021 at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Productive cough, Pyrexia, Sneezing, Vaccination site pain, Wheezing
Clinical narrative: injection site pain; tiredness; headache; fever; nausea; feeling unwell; dizziness; productive cough (yellow-brown); sneezing; weezing (no deep breaths); This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 11:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 the patient experienced injection site pain, tiredness, headache, fever, nausea, feeling unwell, dizziness, productive cough (yellow-brown), sneezing and wheezing (no deep breaths). Therapeutic measures were not taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event injection site pain, tiredness, headache, fever, nausea, feeling unwell, dizziness, productive cough (yellow-brown), sneezing and wheezing (no deep breaths) were recovered with sequelae on Apr2021 at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Nausea; Vomiting; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0169) via an unspecified route of administration in the left arm on 19Apr2021 at 10:30 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8733) via an unspecified route of administration in the left arm on 29Mar2021 at 10:30 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 at 23:45, the patient experienced nausea and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events nausea and vomiting was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Burning sensation, Chills, Dyspnoea, Lip swelling, Pharyngeal swelling
Clinical narrative: 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; I developed chills shaking, and a burning sensation in my neck; I developed chills shaking, and a burning sensation in my neck; My upper lip showed signs of possible swelling; This is a spontaneous report from a contactable consumer. This 27-year-old male consumer (patient) reported for himself. A 27-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration, administered in Arm Left on 19Apr2021 19:15 (at the age of 27 years), (Batch/Lot Number: EW0151) as DOSE 2, SINGLE for covid-19 immunisation at hospital. The patient medical history was not reported. Concomitant medications included One a Day vitamins and omega-3 fatty acids (ALGAE OMEGA 3) taken for an unspecified indication, start and stop date were not reported. The patient previously took Ativan and experienced drug hypersensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 29Mar2021,07:15 PM (Batch/Lot Number: ER8732) as DOSE 1, SINGLE for covid-19 immunisation. Patient stated, on 19Apr2021 23:15, 4 hours after receiving vaccination, "I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minutes of feeling out the situation, I developed chills, shaking, and a burning sensation in my neck. The swelling was more of a personal truth than objective due to the fact that any swelling that was present could not be identified. My upper lip showed signs of possible swelling". The events resulted in visit to emergency room. The patient received treatment for the events as Steroid and Benadryl shot along with a Pepcid. The clinical outcome of the events was recovered in 2021.  No follow-up attempts are Possible. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Tongue oedema
Clinical narrative: 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; 4 hours after receiving vaccination, I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minu; I developed chills shaking, and a burning sensation in my neck; I developed chills shaking, and a burning sensation in my neck; My upper lip showed signs of possible swelling; This is a spontaneous report from a contactable consumer. This 27-year-old male consumer (patient) reported for himself. A 27-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration, administered in Arm Left on 19Apr2021 19:15 (at the age of 27 years), (Batch/Lot Number: EW0151) as DOSE 2, SINGLE for covid-19 immunisation at hospital. The patient medical history was not reported. Concomitant medications included One a Day vitamins and omega-3 fatty acids (ALGAE OMEGA 3) taken for an unspecified indication, start and stop date were not reported. The patient previously took Ativan and experienced drug hypersensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 29Mar2021,07:15 PM (Batch/Lot Number: ER8732) as DOSE 1, SINGLE for covid-19 immunisation. Patient stated, on 19Apr2021 23:15, 4 hours after receiving vaccination, "I woke up because my tongue seemed to be blocking my airway and made it very hard to breathe. I sat up and noticed my throat and tongue felt swollen. After 15 minutes of feeling out the situation, I developed chills, shaking, and a burning sensation in my neck. The swelling was more of a personal truth than objective due to the fact that any swelling that was present could not be identified. My upper lip showed signs of possible swelling". The events resulted in visit to emergency room. The patient received treatment for the events as Steroid and Benadryl shot along with a Pepcid. The clinical outcome of the events was recovered in 2021.  No follow-up attempts are Possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea
Clinical narrative: Cramping has been stronger and hurting more than usual.; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 20Apr2021 at 10:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included ethinylestradiol; drospirenone (YASMIN) from an unknown date for birth control. On 20Apr2021 at 12:00, the patient was currently on period, and experienced cramping had been stronger and hurting more than usual. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event cramping which had been stronger and hurting more than usual was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Nausea, Vaccination site pain
Clinical narrative: Dizziness started about 6 hours later; Nausea; Post-nausea headache; Soreness at the injection site; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 19Apr2021 at 10:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included complex regional pain syndrome/reflex sympathetic dystrophy (CRPS/RSD), COVID-19 and allergy to penicillin and sulfa. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 19Apr2021 at 16:00, about 6 hours after the vaccination, the patient experienced dizziness which increased in intensity and led to nausea and post-nausea headache. Dizziness was yet to subside and the patient was 28 hours in. The patient also experienced soreness at the injection site, as expected. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events dizziness started about 6 hours later, nausea, post-nausea headache and soreness at the injection site were not resolved at the time this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dysphonia, SARS-CoV-2 test
Clinical narrative: Persistent cough; Hoarseness; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 12Apr2021 at 19:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included famotidine (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA) and unspecified vitamins; all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received zolmitriptan (ZOMIG) taken for unknown indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 22Mar2021 at 19:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 16:00, the patient experienced persistent cough and hoarseness. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had been tested for COVID-19. On 16Apr2021, the patient underwent nasal swab test for COVID-19 and the result was negative. Therapeutic measures were taken as a result of the events and included treatment with MUCINEX and TYLENOL. The clinical outcome of the events persistent cough and hoarseness were not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperacusis, Sinus disorder, Tinnitus
Clinical narrative: Tinnitus in left ear; Hyperacusis in left ear; Some light sinus symptoms like scratch tonsils and drainage.; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6204) via an unspecified route of administration in the left arm on 18Mar2021 at 12:30 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL9266) via an unspecified route of administration in the left arm on 25Feb2021 at 17:00 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. On an unknown date in Mar2021, the patient experienced just some light sinus symptoms like scratch tonsils and drainage. On 23Mar2021 at 07:30, 4 days after the vaccination the patient experienced tinnitus and hyperacusis in left ear. The adverse event resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment for the reported events which included prednisone taper. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events light sinus symptoms like scratch tonsils and drainage, tinnitus in left ear and hyperacusis in left ear were recovering at the time of this report   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Paraesthesia
Clinical narrative: Arms feel tingly, like they are falling asleep; Like they are little weak; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 20Apr2021 at 10:45 (at the age of 25-years-old) as a single dose for COVID-19immunisation. Medical history included environmental allergy and allergy to some animals. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin d nos (VITAMIN D) for unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. On 20Apr2021 at 12:15 the patient experienced arms feel tingly, like they're falling asleep and a little weak. No therapeutic measures were taken as a result of reported reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event arms feel tingly and they're falling a little like weak was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: swollen lymph node near left side collarbone; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 08:45 (at the age of 47-years-old) as a single dose for COVID-19 immunization. The patient did not have any relevant medical history. The patient had no allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Mar2021 at 08:45 (at the age of 47-years-old) as a single dose for COVID-19 immunization. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 12:00, the patient experienced swollen lymph node near left side collarbone; noticed on 15Apr2021 and it had reduced in size but was still noticeable. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as result of the event. The clinical outcome of the event swollen lymph node near left side collarbone was resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Fever of at least 101.5; Chills; Body Aches; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 16:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to dairy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced fever of at least 101.5, chills, body aches and injection site soreness. On an unknown date in Apr2021, the patient underwent body temperature and the result was 101.5 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever of at least 101.5, chills, body aches and injection site soreness was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: a raised red and itchy rash on chest and torso lasting for 3-4 days. Was still able to work; fatigue for 1-2 days. Was still able to work; a raised red on chest and torso lasting for 3-4 days; Raised rash on chest and torso lasting 4 days; This is a spontaneous report from a non-contactable nurse. A 70-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;  Lot Number: EN6203) via intramuscular route of administration in the left arm on 20Feb2021 at 14:30 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and COVID-19. The patient was allergic to penicillin. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously received varicella zoster vaccine rgE (SHINGRIX) on 18Jan2021 for indication of immunisation. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient received other vaccines within four weeks prior to the vaccination. On 27Feb2021, the patient experienced a raised red and itchy rash on chest and torso lasting for 3 to 4 days, fatigue for 1 to 2 days. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fatigue was recovered on an unknown date in Feb2021 and the event raised ,itchy, red rash on chest was recovered on an unknown date in Mar2021.    No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Purpura, Rash, Rash pruritic
Clinical narrative: Rash over body, mostly chest, back, arms, legs, neck and face; It itched terribly until scratched; It bled; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on an unknown date in Mar2021 at 15:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patients' medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medications within two weeks of the COVID-19 vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021, the patient experienced rash over body, mostly chest, back, arms, legs, neck and face. The patient reported that it itched terribly until she scratched and it bled. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with an unspecified steroid cream. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash over body, mostly chest, back, arms, legs, neck and face, itched terribly until scratched and it bled were resolving at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the right arm on an unknown date in Apr2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Lymphadenopathy, Mouth ulceration, Pain
Clinical narrative: chills; fever; aches; fatigue; mouth and throat ulcers; mouth and throat ulcers; swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 13Apr2021 at 21:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included history of parotid gland cancer, fully recovered and treatment over 15 years ago. The patient had known allergies to penicillin and sulfa drugs. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) and birth control; both taken from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the left arm on 23Mar2021 at 10:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Apr2021, the first 48 hours, the patient experienced chills, fever, aches and fatigue. The patient also experienced mouth and throat ulcers, swollen lymph nodes, chills, fatigue - still after an entire week. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measure was taken as a result of the events mouth and throat ulcers and included treatment with magic mouthwash prescription. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, aches, fatigue, mouth and throat ulcers and swollen lymph nodes were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Pharyngeal ulceration, Pyrexia
Clinical narrative: chills; fever; aches; fatigue; mouth and throat ulcers; mouth and throat ulcers; swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 13Apr2021 at 21:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included history of parotid gland cancer, fully recovered and treatment over 15 years ago. The patient had known allergies to penicillin and sulfa drugs. Concomitant medications included sertraline (MANUFACTURER UNKNOWN) and birth control; both taken from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the left arm on 23Mar2021 at 10:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Apr2021, the first 48 hours, the patient experienced chills, fever, aches and fatigue. The patient also experienced mouth and throat ulcers, swollen lymph nodes, chills, fatigue - still after an entire week. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measure was taken as a result of the events mouth and throat ulcers and included treatment with magic mouthwash prescription. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, aches, fatigue, mouth and throat ulcers and swollen lymph nodes were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles (Herpes Zoster); This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 17Mar2021 at 12:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient was allergic to penicillin and sulfa drugs. The patient did not receive any medication within 2 weeks of vaccination. The patient previously took cefaclor (CECLOR) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 24Feb2021 at 12:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 19:00, the patient experienced shingles (herpes zoster), which was diagnosed on 14Apr2021. The patient reported that he was a healthy fit 39 year old male with no underlying conditions. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event and included treatment with valacyclovir hydrochloride 1 gram for 7 days. The clinical outcome of the event shingles (herpes zoster) was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.